News

The company’s ANDA product is a generic version of Pfizer and Tris Pharma’s Quillivant XR, which is a central nervous system (CNS) stimulant indicated to treat attention deficit

Currently, OPS202 is evaluated in Phase I/II clinical trials and is based on a new next generation antagonistic somatostatin analog with improved receptor binding to sst2. The company

As part of the deal, Aduro will receive a $30m up-front payment and is also eligible to receive significant development, regulatory and commercialization milestone payments up to a

As part of the development, Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, while Immune Design will provide its preclinical trivalent vaccine product candidate

Type 1 diabetics are unable to produce the insulin required to transport glucose (blood sugar) from the blood to the inside of cells where it is used as

Batu Biologics plans to utilize the licensed technology to enhance the potency of the antigen-specific immune response induced by the company’s novel ValloVax™ lung cancer vaccine. The company

Upon completion of the merger, the combined company changed its name to Bone Biologics, Corp and anticipates that trading in the Company’s common stock will commence on the

The lawsuit was filed as a result of Actavis submitting an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration ("FDA") in which Actavis is

Dr. Vaughan Clift, Ampio’s Chief Regulatory Officer explained "The seven (7) patient ‘open label’ phase of the 47 patient STRUT study was performed to assure that multiple injections